New Data Presented on Gardasil, Merck's Cervical Cancer Vaccine, in Women Through Age 45

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Nov 5, 2007 - GARDASIL(R) (Human Papillomavirus Quadrivalent) (Types 6, 11, 16, 18) Vaccine, Recombinant) prevented 91 percent of cases of persistent infection, low-grade cervical abnormalities, and pre-cancers, and external genital lesions caused by HPV types 6, 11, 16 and 18 compared with placebo in women aged 24 through 45, according to new data presented today at the 24th International Papillomavirus Conference (IPC) in Beijing, China.

The primary results evaluated women who were free of infection from at least one vaccine HPV type when they began the study, and who remained free of infection with the relevant HPV type(s) until they completed the three-dose vaccination regimen. GARDASIL is currently indicated for girls and women 9 through 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV types 6, 11, 16 and 18.

"Women remain at significant risk for acquiring HPV infections and developing HPV-related diseases throughout their lifetime," said Eliav Barr M.D., executive director of Biologics Clinical Research and head of the HPV Vaccine Program, Merck Research Laboratories. "These data build on the clinical program for GARDASIL and will help us to understand the potential benefit that GARDASIL may have in women through age 45."

Merck will submit these data to the U.S. Food and Drug Administration (FDA) before the end of the year to seek an indication for women through age 45.

The international multi-center study, designed to examine if GARDASIL is effective at reducing disease and persistent infection caused by HPV types 6, 11, 16 and 18, involved more than 3,800 women. Women included in the study also had no history of: LEEP (loop electrosurgical excision procedure) or hysterectomy; biopsy-diagnosed cervical HPV disease in the past five years; or history of genital warts.

Because GARDASIL is designed to prevent HPV 6, 11, 16 and 18 disease, rather than treat ongoing infection, the primary analysis of the study was conducted among women who were free of infection with at least one of the relevant HPV types at the start of the trial (baseline), remained free of infection with the relevant type(s) throughout the course of the vaccination period, and who received all three doses of vaccine and placebo. Researchers analyzed the combined incidence of persistent infection, cervical intraepithelial neoplasia (CIN) or external genital lesions caused by the four vaccine HPV types (6, 11, 16 and 18) and disease caused by HPV 16 and 18.

In the primary study analysis, there were 41 cases of persistent infection, CIN or external genital lesions (genital warts and vaginal and vulvar lesions) caused by HPV 6, 11, 16 or 18 in the placebo group compared to four cases in women who received GARDASIL (91 percent reduction in incidence, 95 percent CI: 74 to 98%) over a mean of 1.65 years of follow up. Also as a primary analysis, GARDASIL prevented 83 percent (95% CI: 51 to 96%) of persistent infection, low-grade cervical abnormalities and pre-cancers, and external genital lesions caused by HPV types 16 and 18 alone (23 cases in the placebo group and four cases in the vaccine group). In a secondary endpoint, GARDASIL prevented 100 percent of persistent infections, low-grade cervical abnormalities and pre-cancers, and external genital lesions caused by HPV types 6 and 11.

In addition, GARDASIL reduced HPV 16 and 18-related abnormal Pap test results (measured as a finding of atypical squamous cells of undetermined significant, or ASC-US, with positive HPV probe, or worse diagnoses) by 94 percent (95% CI: 63 to 100%).

In this study, the most common adverse experiences were injection site-related (erythema, pain, pruritus, swelling and warmth); injection site adverse experiences were higher in the vaccine group than placebo group (76.4 percent, 64.2 percent, respectively).

GARDASIL was approved by the FDA on June 8, 2006, and is recommended for use by girls and women ages 11 to 26 by the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. GARDASIL helps protect against the four HPV types (6, 11, 16 and 18) that cause the most disease, including 70 percent of cervical cancer cases and 90 percent of cases of genital warts.

Additional important information about GARDASIL

GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.

The health-care provider should inform the patient, parent or guardian that vaccination does not substitute for routine cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care. GARDASIL is not recommended for use in pregnant women.

Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; CIN, vulvar interepithelial neoplasia (VIN), or vaginal interepithelial neoplasia (VaIN). GARDASIL has not been shown to protect against disease due to other HPV types.

In clinical studies for GARDASIL, vaccine-related adverse experiences that were observed at a frequency of at least 1.0 percent among recipients of GARDASIL and also greater than those observed among recipients of placebo, respectively, were pain (83.9 percent vs. 75.4 percent), swelling (25.4 percent vs. 15.8 percent), erythema (24.6 percent vs. 18.4 percent), fever (10.3 percent vs. 8.6 percent), nausea (4.2 percent vs. 4.1 percent), pruritis (3.1 percent vs. 2.8 percent) and dizziness (2.8 percent vs. 2.6 percent).

Dosage and administration for GARDASIL

GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the upper arm or upper anterior thigh over a six-month period. The following dosage schedule is recommended: first dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

GARDASIL is widely available throughout the United States

There is broad private and public health insurance coverage for GARDASIL. Health plans covering approximately 98 percent of privately insured lives in the U.S. (currently more than 140 insurance plans) have implemented coverage for GARDASIL; however, individual benefit coverage and rates provided by health plans may vary.

GARDASIL was also added to the Vaccines for Children (VFC) Program on November 1, 2006, providing coverage for many who do not have private health insurance. All of the 55 immunization projects in the U.S. have adopted GARDASIL and most are filling provider orders.

Merck has a patient assistance program for vaccines. Through this program, currently available in private physicians' offices and private clinics, Merck is making available, free of charge, GARDASIL and other Merck vaccines indicated for use in individuals ages 19 and older who are uninsured and who are unable to afford vaccines.

GARDASIL is approved in 85 countries

GARDASIL (sold in some countries as SILGARD(R)) has been approved in 85 countries, including the United States, the 27 countries of the European Union, Mexico, Australia, Taiwan, Canada, New Zealand and Brazil, and additional applications are currently under review with regulatory agencies in many more countries around the world. Merck will donate free vaccine to the non-profit organization PATH to support demonstration studies designed to accelerate the availability of cervical cancer vaccines in the most impoverished nations. PATH is funded by a grant from the Bill & Melinda Gates Foundation. Merck is working with India's Council of Medical Research to study GARDASIL in India. At the 2007 Clinton Global Initiative, Merck committed to donate at least three million doses of GARDASIL to support vaccination programs in the lowest income nations. Merck will make its newer vaccines, including GARDASIL, available to developing world countries at dramatically lower prices at which Merck will not profit.

HPV is a common infection

In the United States, approximately 20 million people are infected with HPV, and approximately 80 percent of females will have acquired HPV by age 50. For most people, HPV goes away on its own; however in some, certain high-risk types of HPV, if unrecognized and untreated, can lead to cervical cancer. Cervical cancer is the second most common cause of cancer death in women worldwide, resulting in nearly a half-million diagnoses and 240,000 deaths each year. It is estimated that in 2007, there will be approximately 11,150 new cases of cervical cancer and 3,700 deaths in the United States. Approximately 6,000 cases of vulvar or vaginal cancer are diagnosed annually in the U.S. HPV-related diseases, including screening, follow up and treatment, costs about $5 billion per year in the U.S. HPV 16 and 18 cause an important proportion of these lesions and related costs.

Certain low-risk types of HPV cause genital warts and can lead to abnormal Pap results. Approximately one million cases of genital warts occur each year in the United States and an estimated 32 million cases occur worldwide. Additionally, there are an estimated 4.7 million abnormal Pap results that require follow-up each year in the United States. At least 3 million of these results are caused by some type of HPV.

Other Information about GARDASIL

In 1995, Merck entered into a license agreement and research collaboration with CSL Limited of Australia relating to technology used in GARDASIL. GARDASIL also is the subject of other third-party licensing agreements.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Prescribing information and patient product information for GARDASIL(R) is attached and is also available at www.gardasil.com.

GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, U.S.A. -0-

MERCK & CO., INC.

Whitehouse Station, NJ 08889, USA                              9682305

----------------------------------------------------------------------

GARDASIL(R)

(Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant)

DESCRIPTION

GARDASIL* is a non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs. The fermentation process involves growth of S. cerevisiae on chemically-defined fermentation media which include vitamins, amino acids, mineral salts, and carbohydrates. The VLPs are released from the yeast cells by cell disruption and purified by a series of chemical and physical methods. The purified VLPs are adsorbed on preformed aluminum-containing adjuvant (amorphous aluminum hydroxyphosphate sulfate). The quadrivalent HPV VLP vaccine is a sterile liquid suspension that is prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer.

GARDASIL is a sterile preparation for intramuscular administration. Each 0.5-mL dose contains approximately 20 mcg of HPV 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein.

Each 0.5-mL dose of the vaccine contains approximately 225 mcg of aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, and water for injection. The product does not contain a preservative or antibiotics.

After thorough agitation, GARDASIL is a white, cloudy liquid.

CLINICAL PHARMACOLOGY

Disease Burden

Human Papillomavirus (HPV) causes squamous cell cervical cancer (and its histologic precursor lesions Cervical Intraepithelial Neoplasia (CIN) 1 or low grade dysplasia and CIN 2/3 or moderate to high grade dysplasia) and cervical adenocarcinoma (and its precursor lesion adenocarcinoma in situ (AIS)). HPV also causes approximately 35-50% of vulvar and vaginal cancers. Vulvar Intraepithelial Neoplasia (VIN) Grade 2/3 and Vaginal Intraepithelial Neoplasia (VaIN) Grade 2/3 are immediate precursors to these cancers.

Cervical cancer prevention focuses on routine screening and early intervention. This strategy has reduced cervical cancer rates by approximately 75% in compliant individuals by monitoring and removing premalignant dysplastic lesions.

HPV also causes genital warts (condyloma acuminata) which are growths of the cervicovaginal, vulvar, and the external genitalia that rarely progress to cancer. HPV 6, 11, 16, and 18 are common HPV types.

HPV 16 and 18 cause approximately:

-- 70% of cervical cancer, AIS, CIN 3, VIN 2/3, and VaIN 2/3 cases; and

-- 50% of CIN 2 cases.

HPV 6, 11, 16, and 18 cause approximately:

-- 35 to 50% of all CIN 1, VIN 1, and VaIN 1 cases; and

-- 90% of genital wart cases.

Mechanism of Action

HPV only infects humans, but animal studies with analogous (animal, not human) papillomaviruses suggest that the efficacy of L1 VLP vaccines is mediated by the development of humoral immune responses.

CLINICAL STUDIES

CIN 2/3 and AIS are the immediate and necessary precursors of squamous cell carcinoma and adenocarcinoma of the cervix, respectively. Their detection and removal has been shown to prevent cancer; thus, they serve as surrogate markers for prevention of cervical cancer.

Efficacy was assessed in 4 placebo-controlled, double-blind, randomized Phase II and III clinical studies. The first Phase II study evaluated the HPV 16 component of GARDASIL (Protocol 005, N = 2391) and the second evaluated all components of GARDASIL (Protocol 007, N = 551). The Phase III studies, termed FUTURE (Females United To Unilaterally Reduce Endo/Ectocervical Disease), evaluated GARDASIL in 5442 (FUTURE I or Protocol 013) and 12,157 (FUTURE II or Protocol 015) subjects. Together, these four studies evaluated 20,541 women 16 to 26 years of age at enrollment. The median duration of follow-up was 4.0, 3.0, 2.4, and 2.0 years for Protocol 005, Protocol 007, FUTURE I, and FUTURE II, respectively. Subjects received vaccine or placebo on the day of enrollment, and 2 and 6 months thereafter. Efficacy was analyzed for each study individually and for all studies combined according to a prospective clinical plan.

Prophylactic Efficacy

GARDASIL is designed to prevent HPV 6-, 11-, 16-, and/or 18-related cervical cancer, cervical dysplasias, vulvar or vaginal dysplasias, or genital warts. GARDASIL was administered without prescreening for presence of HPV infection and the efficacy trials allowed enrollment of subjects regardless of baseline HPV status (i.e., Polymerase Chain Reaction (PCR) status or serostatus). Subjects who were infected with a particular vaccine HPV type (and who may already have had disease due to that infection) were not eligible for prophylactic efficacy evaluations for that type.

The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population, consisting of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naive (PCR negative in cervicovaginal specimens and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). Efficacy was measured starting after the Month 7 visit.

Overall, 73% of subjects were naive (i.e., PCR negative and seronegative for all 4 vaccine HPV types) to all 4 vaccine HPV types at enrollment.

A total of 27% of subjects had evidence of prior exposure to or ongoing infection with at least 1 of the 4 vaccine HPV types. Among these subjects, 74% had evidence of prior exposure to or ongoing infection with only 1 of the 4 vaccine HPV types and were naive (PCR negative and seronegative) to the remaining 3 types.

In subjects who were naive (PCR negative and seronegative) to all 4 vaccine HPV types, CIN, genital warts, VIN, and VaIN caused by any of the 4 vaccine HPV types were counted as endpoints.

Among subjects who were positive (PCR positive and/or seropositive) for a vaccine HPV type at Day 1, endpoints related to that type were not included in the analyses of prophylactic efficacy. Endpoints related to the remaining types for which the subject was naive (PCR negative and seronegative) were counted.

For example, in subjects who were HPV 18 positive (PCR positive and/or seropositive) at Day 1, lesions caused by HPV 18 were not counted in the prophylactic efficacy evaluations. Lesions caused by HPV 6, 11, and 16 were included in the prophylactic efficacy evaluations. The same approach was used for the other types.

GARDASIL was efficacious in reducing the incidence of CIN (any grade including CIN 2/3); AIS; genital warts; VIN (any grade); and VaIN (any grade) related to vaccine HPV types in those who were PCR negative and seronegative at baseline (Table 1). -0-

                               Table 1

      Analysis of Efficacy of GARDASIL in the PPE* Population**

----------------------------------------------------------------------

                         GARDASIL     Placebo

                       -------------------------

      Population             Number      Number  % Efficacy (95% CI)

                         n     of    n     of

                              cases       cases

======================================================================

HPV 16- or 18-related CIN 2/3 or AIS

----------------------------------------------------------------------

    Protocol 005***     755    0    750    12    100.0 (65.1, 100.0)

----------------------------------------------------------------------

     Protocol 007       231    0    230    1    100.0 (-3734.9, 100.0)

----------------------------------------------------------------------

       FUTURE I         2200   0    2222   19    100.0 (78.5, 100.0)

----------------------------------------------------------------------

       FUTURE II        5301   0    5258   21    100.0+ (80.9, 100.0)

----------------------------------------------------------------------

 Combined Protocols++   8487   0    8460   53    100.0+ (92.9, 100.0)

----------------------------------------------------------------------

HPV 6-, 11-, 16-, 18-related CIN (CIN 1, CIN 2/3) or AIS

----------------------------------------------------------------------

     Protocol 007       235    0    233    3    100.0 (-137.8, 100.0)

----------------------------------------------------------------------

       FUTURE I         2240   0    2258   37    100.0+ (89.5, 100.0)

----------------------------------------------------------------------

       FUTURE II        5383   4    5370   43     90.7 (74.4, 97.6)

----------------------------------------------------------------------

  Combined Protocols    7858   4    7861   83     95.2 (87.2, 98.7)

======================================================================

HPV 6-, 11-, 16-, or 18-related Genital Warts

----------------------------------------------------------------------

     Protocol 007       235    0    233    3    100.0 (-139.5, 100.0)

----------------------------------------------------------------------

       FUTURE I         2261   0    2279   29    100.0 (86.4, 100.0)

----------------------------------------------------------------------

       FUTURE II        5401   1    5387   59     98.3 (90.2, 100.0)

----------------------------------------------------------------------

  Combined Protocols    7897   1    7899   91     98.9 (93.7, 100.0)

----------------------------------------------------------------------

* The PPE population consisted of individuals who received all 3

 vaccinations within 1 year of enrollment, did not have major

 deviations from the study protocol, and were naive (PCR negative and

 seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18)

 prior to dose 1 and through 1 month Postdose 3 (Month 7).

**See Table 2 for analysis of vaccine impact in the general

 population.

***Evaluated only the HPV 16 L1 VLP vaccine component of GARDASIL.

+P-values were computed for pre-specified primary hypothesis tests.

 All p-values were <0.001, supporting the following conclusions:

 efficacy against HPV 16/18-related CIN 2/3 is >0% (FUTURE II);

 efficacy against HPV 16/18-related CIN 2/3 is >25% (Combined

 Protocols); and efficacy against HPV 6/11/16/18-related CIN is >20%

 (FUTURE I).

++Analyses of the combined trials were prospectively planned and

 included the use of similar study entry criteria.

n = Number of subjects with at least 1 follow-up visit after Month 7.

Note 1: Point estimates and confidence intervals are adjusted for

 person-time of follow-up.

Note 2: The first analysis in the table (i.e., HPV 16- or 18-related

 CIN 2/3, AIS or worse) was the primary endpoint of the vaccine

 development plan.

Note 3: FUTURE I refers to Protocol 013; FUTURE II refers to Protocol

 015.

----------------------------------------------------------------------

GARDASIL was efficacious against HPV disease caused by each of the 4 vaccine HPV types.

In a pre-defined analysis, the efficacy of GARDASIL against HPV 16/18-related disease was 100% (95% CI: 87.9%, 100.0%) for CIN 3 or AIS and 100% (95% CI: 55.5%, 100.0%) for VIN 2/3 or VaIN 2/3. The efficacy of GARDASIL against HPV 6-, 11-, 16-, and 18-related VIN 1 or VaIN 1 was 100% (95% CI: 75.8%, 100.0%). These analyses were conducted in the PPE population that consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naive (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).

Efficacy in Subjects with Current or Prior Infection

GARDASIL is a prophylactic vaccine.

There was no clear evidence of protection from disease caused by HPV types for which subjects were PCR positive and/or seropositive at baseline.

Individuals who were already infected with 1 or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV types.

General Population Impact

The general population of young American women includes women who are HPV-naive (PCR negative and seronegative) and women who are HPV-non-naive (PCR positive and/or seropositive), some of whom have HPV-related disease. The clinical trials population approximated the general population of American women with respect to prevalence of HPV infection and disease at enrollment. Analyses were conducted to evaluate the overall impact of GARDASIL with respect to HPV 6-, 11-, 16-, and 18-related cervical and genital disease in the general population. Here, analyses included events arising from HPV infections that were present at the start of vaccination as well as events that arose from infections that were acquired after the start of vaccination.

The impact of GARDASIL in the general population is shown in Table 2. Impact was measured starting 1 month Postdose 1. Prophylactic efficacy denotes the vaccine's efficacy in women who are naive (PCR negative and seronegative) to the relevant HPV types at vaccination onset. General population impact denotes vaccine impact among women regardless of baseline PCR status and serostatus. The majority of CIN and genital warts, VIN, and VaIN detected in the group that received GARDASIL occurred as a consequence of HPV infection with the relevant HPV type that was already present at Day 1. -0-

                               Table 2

           General Population Impact for Vaccine HPV Types

----------------------------------------------------------------------

                           GARDASIL or

                            HPV 16 L1    Placebo

                               VLP

                             Vaccine                  % Reduction

  Endpoints     Analysis  -------------------------     (95% CI)

                            N   Cases   N   Cases

======================================================================

              Prophylactic

                Efficacy*  9342   1    9400   81   98.8 (92.9, 100.0)

             ---------------------------------------------------------

 HPV 16- or     HPV 16

 18-related    and/or HPV

 CIN 2/3 or    18 Positive

     AIS        at Day 1    --   121    --   120           --

             ---------------------------------------------------------

                General

               Population

                Impact**   9831  122   9896  201    39.0 (23.3, 51.7)

======================================================================

              Prophylactic

                Efficacy*  8641   0    8667   24   100.0 (83.3, 100.0)

             ---------------------------------------------------------

 HPV 16- or     HPV 16

 18-related    and/or HPV

 VIN 2/3 and   18 Positive

   VaIN 2/3     at Day 1    --    8     --    2            --

             ---------------------------------------------------------

                General

               Population

                Impact**   8954   8    8962   26    69.1 (29.8, 87.9)

======================================================================

              Prophylactic

                Efficacy*  8625   9    8673  143    93.7 (87.7, 97.2)

             ---------------------------------------------------------

HPV 6-, 11-,  HPV 6, HPV

   16-, 18-    11, HPV 16,

 related CIN   and/or HPV       161***      174***

 (CIN 1, CIN   18 Positive

 2/3) or AIS    at Day 1    --          --                 --

             ---------------------------------------------------------

                General

               Population

                Impact**   8814  170   8846  317    46.4 (35.2, 55.7)

======================================================================

              Prophylactic

                Efficacy*  8760   9    8786  136    93.4 (87.0, 97.0)

             ---------------------------------------------------------

HPV 6-, 11-,  HPV 6, HPV

 16-, or 18-   11, HPV 16,

   related     and/or HPV                    48+

   Genital     18 Positive

    Warts       at Day 1    --    49    --                 --

             ---------------------------------------------------------

                General

               Population

                Impact**   8954   58   8962  184    68.5 (57.5, 77.0)

----------------------------------------------------------------------

*Includes all subjects who received at least 1 vaccination and who

 were naive (PCR negative and seronegative) to HPV 6, 11, 16, and/or

 18 at Day 1. Case counting started at 1 Month Postdose 1.

**Includes all subjects who received at least 1 vaccination

 (regardless of baseline HPV status at Day 1). Case counting started

 at 1 Month Postdose 1.

***Includes 2 subjects (1 in each vaccination group) who underwent

 colposcopy for reasons other than an abnormal Pap and 1 placebo

 subject with missing serology/PCR data at day 1.

+Includes 1 subject with missing serology/PCR data at day 1.

Note 1: The 16- and 18-related CIN 2/3 or AIS composite endpoint

 included data from studies 005, 007, 013, and 015. All other

 endpoints only included data from studies 007, 013, and 015.

Note 2: Positive status at Day 1 denotes PCR positive and/or

 seropositive for the respective type at Day 1.

Note 3: Percent reduction includes the prophylactic efficacy of

 GARDASIL as well as the impact of GARDASIL on the course of

 infections present at the start of the vaccination.

Note 4: Table 2 does not include disease due to non-vaccine HPV types.

----------------------------------------------------------------------

GARDASIL does not prevent infection with the HPV types not contained in the vaccine. Cases of disease due to non-vaccine types were observed among recipients of GARDASIL and placebo in Phase II and Phase III efficacy studies.

Among cases of CIN 2/3 or AIS caused by vaccine or non-vaccine HPV types in subjects in the general population who received GARDASIL, 79% occurred in subjects who had an abnormal Pap test at Day 1 and/or who were positive (PCR positive and/or seropositive) to HPV 6, 11, 16, and/or 18 at Day 1.

An interim analysis of the general population impact for GARDASIL was performed from studies 007, 013, and 015 that had a median duration of follow-up of 1.9 years. GARDASIL reduced the overall rate of CIN 2/3 or AIS caused by vaccine or non-vaccine HPV types by 12.2% (95% CI: -3.2%, 25.3%), compared with placebo.

An analysis of overall population impact for the HPV 16 L1 VLP vaccine was conducted from study 005 that had a median duration of follow-up of 3.9 years. The HPV 16 L1 VLP vaccine reduced the overall incidence of CIN 2/3 caused by vaccine or non-vaccine HPV types by 32.7% (95% CI: -34.7%, 67.3%) through a median duration of follow-up of 1.9 years (fixed case analysis) and by 45.3% (95% CI: 10.9%, 67.1%), through a median duration of follow-up of 3.9 years (end of study).

GARDASIL reduced the incidence of definitive therapy (e.g., loop electrosurgical excision procedure, laser conization, cold knife conization) by 16.5% (95% CI: 2.9%, 28.2%), and surgery to excise external genital lesions by 26.5% (95% CI: 3.6%, 44.2%), compared with placebo for all HPV-related diseases. These analyses were performed in the general population of women which includes women regardless of baseline HPV PCR status or serostatus. GARDASIL has not been shown to protect against the diseases caused by all HPV types and will not treat existing disease caused by the HPV types contained in the vaccine. The overall efficacy of GARDASIL, described above, will depend on the baseline prevalence of HPV infection related to vaccine types in the population vaccinated and the incidence of HPV infection due to types not included in the vaccine.

Immunogenicity

Assays to Measure Immune Response

Because there were few disease cases in subjects naive (PCR negative and seronegative) to vaccine HPV types at baseline in the group that received GARDASIL, it has not been possible to establish minimum anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 antibody levels that protect against clinical disease caused by HPV 6, 11, 16, and/or 18.

The immunogenicity of GARDASIL was assessed in 8915 women (GARDASIL N = 4666; placebo N = 4249) 18 to 26 years of age and female adolescents 9 to 17 years of age (GARDASIL N = 1471; placebo N = 583).

Type-specific competitive immunoassays with type-specific standards were used to assess immunogenicity to each vaccine HPV type. These assays measured antibodies against neutralizing epitopes for each HPV type. The scales for these assays are unique to each HPV type; thus, comparisons across types and to other assays are not appropriate.

Immune Response to GARDASIL

The primary immunogenicity analyses were conducted in a per-protocol immunogenicity (PPI) population. This population consisted of individuals who were seronegative and PCR negative to the relevant HPV type(s) at enrollment, remained HPV PCR negative to the relevant HPV type(s) through 1 month Postdose 3 (Month 7), received all 3 vaccinations, and did not deviate from the study protocol in ways that could interfere with the effects of the vaccine.

Overall, 99.8%, 99.8%, 99.8%, and 99.5% of girls and women who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3 across all age groups tested. Anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs peaked at Month 7. GMTs declined through Month 24 and then stabilized through Month 36 at levels above baseline (Table 3). The duration of immunity following a complete schedule of immunization with GARDASIL has not been established. -0-

                               Table 3

Summary of Anti-HPV cLIA Geometric Mean Titers in the PPI* Population

----------------------------------------------------------------------

                                                        Aluminum-

                                 GARDASIL               Containing

                                N** = 276                 Placebo

                                                         N = 275

      Study Time      ------------------------------------------------

                             Geometric Mean Titer       Geometric Mean

                       n***         (95% CI)         n    Titer (95%

                                    mMU/mL+                   CI)

                                                            mMU/mL

======================================================================

Anti-HPV 6

----------------------------------------------------------------------

       Month 07        208   582.2 (527.2, 642.8)   198 4.6 (4.3, 4.8)

----------------------------------------------------------------------

       Month 24        192    93.7 (82.2, 106.9)    188 4.6 (4.3, 5.0)

----------------------------------------------------------------------

       Month 36        183    93.8 (81.0, 108.6)    184 5.1 (4.7, 5.6)

----------------------------------------------------------------------

                             Anti-HPV 11

----------------------------------------------------------------------

       Month 07        208   696.5 (617.8, 785.2)   198 4.1 (4.0, 4.2)

----------------------------------------------------------------------

       Month 24        190    97.1 (84.2, 112.0)    188 4.2 (4.0, 4.3)

----------------------------------------------------------------------

       Month 36        174    91.7 (78.3, 107.3)    180 4.4 (4.1, 4.7)

----------------------------------------------------------------------

Anti-HPV 16

----------------------------------------------------------------------

       Month 07        193  3889.0 (3318.7, 4557.4) 185 6.5 (6.2, 6.9)

----------------------------------------------------------------------

       Month 24        174   393.0 (335.7, 460.1)   175 6.8 (6.3, 7.4)

----------------------------------------------------------------------

       Month 36        176   507.3 (434.6, 592.0)   170 7.7 (6.8, 8.8)

----------------------------------------------------------------------

Anti-HPV 18

----------------------------------------------------------------------

       Month 07        219   801.2 (693.8, 925.4)   209 4.6 (4.3, 5.0)

----------------------------------------------------------------------

       Month 24        204     59.9 (49.7, 72.2)    199 4.6 (4.3, 5.0)

----------------------------------------------------------------------

       Month 36        196     59.7 (48.5, 73.5)    193 4.8 (4.4, 5.2)

----------------------------------------------------------------------

* The PPI population consisted of individuals who received all 3

 vaccinations within pre-defined day ranges, did not have major

 deviations from the study protocol, met predefined criteria for the

 interval between the Month 6 and Month 7 visit, and were naive (PCR

 negative and seronegative) to the relevant HPV type(s) (Types 6, 11,

 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).

**Number of subjects randomized to the respective vaccination group

 who received at least 1 injection.

***Number of subjects in the per-protocol analysis with data at the

 specified study time point.

+mMU = milli-Merck units.

Note: These data are from Protocol 007.

----------------------------------------------------------------------

Table 4 compares anti-HPV GMTs 1 month Postdose 3 among subjects who received Dose 2 between Month 1 and Month 3 and subjects who received Dose 3 between Month 4 and Month 8 (Table 4). -0-

                               Table 4

           Summary of GMTs for Variation of Dosing Regimen

----------------------------------------------------------------------


                                 Anti-HPV 6          Anti-HPV 11

Variation of Dosing Regimen ------------------------------------------

                              N        GMT        N        GMT

                                     (95% CI)            (95% CI)

======================================================================

Dose 2

----------------------------------------------------------------------

 Early*                               570.9               824.6

                             883  (542.2, 601.2) 888  (776.7, 875.5)

----------------------------------------------------------------------

 On Time*                             552.3               739.7

                             1767 (532.3, 573.1) 1785 (709.3, 771.5)

----------------------------------------------------------------------

 Late*                                447.4               613.9

                             313  (405.3, 493.8) 312  (550.8, 684.2)

----------------------------------------------------------------------

Dose 3

----------------------------------------------------------------------

 Early**                              493.1               658.9

                             495  (460.8, 527.8) 501  (609.5, 712.2)

----------------------------------------------------------------------

 On Time**                            549.6               752.8

                             2081 (531.1, 568.8) 2093 (723.8, 782.9)

----------------------------------------------------------------------

 Late**                               589.0               865.3

                             335  (537.0, 645.9) 339  (782.6, 956.7)

----------------------------------------------------------------------


                                  Anti-HPV 16          Anti-HPV 18

Variation of Dosing Regimen ------------------------------------------

                              N         GMT         N        GMT

                                      (95% CI)             (95% CI)

======================================================================

Dose 2

----------------------------------------------------------------------

 Early*                                2625.3               517.7

                             854  (2415.1, 2853.9) 926  (482.9, 555.0)

----------------------------------------------------------------------

 On Time*                              2400.0               473.9

                             1737 (2263.9, 2544.3) 1894 (451.8, 497.1)

----------------------------------------------------------------------

 Late*                                 1889.7               388.5

                             285  (1624.4, 2198.5) 334  (348.3, 433.3)

----------------------------------------------------------------------

Dose 3

----------------------------------------------------------------------

 Early**                               2176.6               423.4

                             487  (1953.4, 2425.3) 521  (388.8, 461.2)

----------------------------------------------------------------------

 On Time**                             2415.0               486.0

                             2015 (2286.3, 2550.9) 2214 (464.7, 508.2)

----------------------------------------------------------------------

 Late**                                2765.9               498.5

                             326  (2408.7, 3176.2) 361  (446.2, 557.0)

----------------------------------------------------------------------


*Early = 36 to 50 days Postdose 1; On Time = 51 to 70 days Postdose 1;

 Late = 71 to 84 days Postdose 1.

**Early = 80 to 105 days Postdose 2; On Time = 106 to 137 days

 Postdose 2; Late = 138 to 160 days Postdose 2.

Note: GMT = Geometric mean titer in mMU/mL (mMU = milli-Merck units.)

----------------------------------------------------------------------

Bridging the Efficacy of GARDASIL from Young Adult Women to Adolescent Girls

A clinical study compared anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs in 10- to 15-year-old girls with responses in 16- to 23-year-old adolescent and young adult women. Among subjects who received GARDASIL, 99.1 to 100% became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive by 1 month Postdose 3.

Table 5 compares the 1 month Postdose 3 anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs in 9- to 15-year-old girls with those in 16- to 26-year-old adolescent and young adult women. -0-

                               Table 5

Immunogenicity Bridging Between 9- to 15-year-old Female Adolescents

                  and 16- to 26-year-old Adult Women

----------------------------------------------------------------------

               9- to 15-year-old Female    16- to 26-year-old Adult

                      Adolescents                     Women

                (Protocols 016 and 018)     (Protocols 013 and 015)

    Assay              N = 1121                     N = 4229

   (cLIA)    ---------------------------------------------------------

               n   GMT       (95% CI)      n    GMT       (95% CI)

======================================================================

 Anti-HPV 6   915 928.7   (874.0, 986.8)  2631 542.6   (526.2, 559.6)

----------------------------------------------------------------------

 Anti-HPV 11  915 1303.0 (1223.1, 1388.0) 2655 761.5   (735.3, 788.6)

----------------------------------------------------------------------

 Anti-HPV 16  913 4909.2 (4547.6, 5299.5) 2570 2293.9 (2185.0, 2408.2)

----------------------------------------------------------------------

 Anti-HPV 18  920 1039.8 (964.9, 1120.4)  2796 461.6   (444.0, 480.0)

----------------------------------------------------------------------

Note: GMT = Geometric mean titer in mMU/mL (mMU = milli-Merck units).

----------------------------------------------------------------------

Anti-HPV responses 1 month Postdose 3 among 9- to 15-year-old girls were non-inferior to anti-HPV responses in 16- to 26-year-old adolescent and young adult women in the combined database of immunogenicity studies for GARDASIL.

On the basis of this immunogenicity bridging, the efficacy of GARDASIL in 9- to 15-year-old girls is inferred.

Studies with Other Vaccines

The safety and immunogenicity of co-administration of GARDASIL with hepatitis B vaccine (recombinant) (same visit, injections at separate sites) were evaluated in a randomized study of 1871 women aged 16 to 24 years at enrollment. Immune response to both hepatitis B vaccine (recombinant) and GARDASIL was non-inferior whether they were administered at the same visit or at a different visit.

INDICATIONS AND USAGE

GARDASIL is a vaccine indicated in girls and women 9-26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18:

-- Cervical cancer

-- Genital warts (condyloma acuminata)

and the following precancerous or dysplastic lesions:

-- Cervical adenocarcinoma in situ (AIS)

-- Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3

-- Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3

-- Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3

-- Cervical intraepithelial neoplasia (CIN) grade 1

CONTRAINDICATIONS

Hypersensitivity to the active substances or to any of the excipients of the vaccine.

Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of GARDASIL should not receive further doses of GARDASIL.

PRECAUTIONS

General

As for any vaccine, vaccination with GARDASIL may not result in protection in all vaccine recipients.

This vaccine is not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN.

This vaccine will not protect against diseases that are not caused by HPV.

GARDASIL has not been shown to protect against diseases due to non-vaccine HPV types.

As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.

The decision to administer or delay vaccination because of a current or recent febrile illness depends largely on the severity of the symptoms and their etiology. Low-grade fever itself and mild upper respiratory infection are not generally contraindications to vaccination.

Individuals with impaired immune responsiveness, whether due to the use of immunosuppressive therapy, a genetic defect, Human Immunodeficiency Virus (HIV) infection, or other causes, may have reduced antibody response to active immunization (see PRECAUTIONS, Drug Interactions).

As with other intramuscular injections, GARDASIL should not be given to individuals with bleeding disorders such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer GARDASIL to such persons, it should be given with steps to avoid the risk of hematoma following the injection.

Information for the Patient, Parent, or Guardian

The health care provider should inform the patient, parent, or guardian that vaccination does not substitute for routine cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care.

The health care provider should provide the vaccine information required to be given with each vaccination to the patient, parent, or guardian.

The health care provider should inform the patient, parent, or guardian of the benefits and risks associated with vaccination. For risks associated with vaccination, see PRECAUTIONS and ADVERSE REACTIONS.

GARDASIL is not recommended for use in pregnant women.

The health care provider should inform the patient, parent, or guardian of the importance of completing the immunization series unless contraindicated.

Patients, parents, or guardians should be instructed to report any adverse reactions to their health care provider.

Drug Interactions

Use with Other Vaccines

Results from clinical studies indicate that GARDASIL may be administered concomitantly (at a separate injection site) with hepatitis B vaccine (recombinant) (see CLINICAL PHARMACOLOGY, Studies with Other Vaccines). Co-administration of GARDASIL with other vaccines has not been studied.

Use with Hormonal Contraceptives

In clinical studies, 13,293 subjects (vaccine = 6644; placebo = 6649) who had post-Month 7 follow-up used hormonal contraceptives for a total of 17,597 person-years (65.1% of the total follow-up time in the studies). Use of hormonal contraceptives or lack of use of hormonal contraceptives among study participants did not alter vaccine efficacy in the PPE population.

Use with Systemic Immunosuppressive Medications

Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines (see PRECAUTIONS, General).

Carcinogenesis, Mutagenesis, Impairment of Fertility

GARDASIL has not been evaluated for the potential to cause carcinogenicity or genotoxicity.

GARDASIL administered to female rats at a dose of 120 mcg total protein, which corresponds to approximately 300-fold excess relative to the projected human dose, had no effects on mating performance, fertility, or embryonic/fetal survival.

Pregnancy

Pregnancy Category B:

Reproduction studies have been performed in female rats at doses up to 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired female fertility or harm to the fetus due to GARDASIL. However, it is not known whether GARDASIL can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. GARDASIL should be given to a pregnant woman only if clearly needed. An evaluation of the effect of GARDASIL on embryo-fetal, pre- and postweaning development was conducted using rats. One group of rats was administered GARDASIL twice prior to gestation, during the period of organogenesis (gestation day 6) and on lactation day 7. A second group of pregnant rats was administered GARDASIL during the period of organogenesis (gestation day 6) and on lactation day 7 only. GARDASIL was administered at 0.5 mL/rat/occasion (approximately 300-fold excess relative to the projected human dose on a mg/kg basis) by intramuscular injection. No adverse effects on mating, fertility, pregnancy, parturition, lactation, embryo-fetal or pre- and postweaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study. In addition, there were no treatment-related effects on developmental signs, behavior, reproductive performance, or fertility of the offspring. The effect of GARDASIL on male fertility has not been studied.

In clinical studies, women underwent urine pregnancy testing prior to administration of each dose of GARDASIL. Women who were found to be pregnant before completion of a 3-dose regimen of GARDASIL were instructed to defer completion of their vaccination regimen until resolution of the pregnancy.

During clinical trials, 2266 women (vaccine = 1115 vs. placebo = 1151) reported at least 1 pregnancy each. Overall, the proportions of pregnancies with an adverse outcome were comparable in subjects who received GARDASIL and subjects who received placebo. Overall, 40 and 41 subjects in the group that received GARDASIL or placebo, respectively (3.6% and 3.6% of all subjects who reported a pregnancy in the respective vaccination groups), experienced a serious adverse experience during pregnancy. The most common events reported were conditions that can result in Caesarean section (e.g., failure of labor, malpresentation, cephalopelvic disproportion), premature onset of labor (e.g., threatened abortions, premature rupture of membranes), and pregnancy-related medical problems (e.g., pre-eclampsia, hyperemesis). The proportions of pregnant subjects who experienced such events were comparable between the vaccination groups.

There were 15 cases of congenital anomaly in pregnancies that occurred in subjects who received GARDASIL and 16 cases of congenital anomaly in pregnancies that occurred in subjects who received placebo.

Further sub-analyses were conducted to evaluate pregnancies with estimated onset within 30 days or more than 30 days from administration of a dose of GARDASIL or placebo. For pregnancies with estimated onset within 30 days of vaccination, 5 cases of congenital anomaly were observed in the group that received GARDASIL compared to 0 cases of congenital anomaly in the group that received placebo. The congenital anomalies seen in pregnancies with estimated onset within 30 days of vaccination included pyloric stenosis, congenital megacolon, congenital hydronephrosis, hip dysplasia and club foot. Conversely, in pregnancies with onset more than 30 days following vaccination, 10 cases of congenital anomaly were observed in the group that received GARDASIL compared with 16 cases of congenital anomaly in the group that received placebo. The types of anomalies observed were consistent (regardless of when pregnancy occurred in relation to vaccination) with those generally observed in pregnancies in women aged 16 to 26 years.

Pregnancy Registry for GARDASIL

Merck & Co., Inc. maintains a Pregnancy Registry to monitor fetal outcomes of pregnant women exposed to GARDASIL. Patients and health care providers are encouraged to report any exposure to GARDASIL during pregnancy by calling (800) 986-8999.

Lactation

It is not known whether vaccine antigens or antibodies induced by the vaccine are excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when GARDASIL is administered to a nursing woman.

A total of 995 nursing mothers (vaccine = 500, placebo = 495) were given GARDASIL or placebo during the vaccination period of the clinical trials. GMTs in nursing and non-nursing mothers were as follows:

The GMTs in nursing mothers were 595.9 (95% CI: 522.5, 679.5) for anti-HPV 6, 864.3 (95% CI: 754.0, 990.8) for anti-HPV 11, 3056.9 (95% CI: 2594.4, 3601.8) for anti-HPV 16, and 527.2 (95% CI: 450.9, 616.5) for anti-HPV 18. The GMTs for women who did not nurse during vaccine administration were 540.1 (95% CI: 523.5, 557.2) for anti-HPV 6, 746.3 (95% CI: 720.4, 773.3) for anti-HPV 11, 2290.8 (95% CI: 2180.7, 2406.3) for anti-HPV 16, and 456.0 (95% CI: 438.4, 474.3) for anti-HPV 18.

Overall, 17 and 9 infants of subjects who received GARDASIL or placebo, respectively (representing 3.4% and 1.8% of the total number of subjects who were breast-feeding during the period in which they received GARDASIL or placebo, respectively), experienced a serious adverse experience. None was judged by the investigator to be vaccine related.

In clinical studies, a higher number of breast-feeding infants (n = 6) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post-vaccination of the mother as compared to infants (n = 2) whose mothers received placebo. In these studies, the rates of other adverse experiences in the mother and the nursing infant were comparable between vaccination groups.

Pediatric Use

The safety and efficacy of GARDASIL have not been evaluated in children younger than 9 years.

Geriatric Use

The safety and efficacy of GARDASIL have not been evaluated in adults above the age of 26 years.

ADVERSE REACTIONS

In 5 clinical trials (4 placebo-controlled), subjects were administered GARDASIL or placebo on the day of enrollment, and approximately 2 and 6 months thereafter. Few subjects (0.1%) discontinued due to adverse experiences. In all except 1 of the clinical trials, safety was evaluated using vaccination report card (VRC)-aided surveillance for 14 days after each injection of GARDASIL or placebo. The subjects who were monitored using VRC-aided surveillance included 5088 girls and women 9 through 26 years of age at enrollment who received GARDASIL and 3790 girls and women who received placebo.

Common Adverse Experiences

Vaccine-related Common Adverse Experiences

The vaccine-related adverse experiences that were observed among female recipients of GARDASIL at a frequency of at least 1.0% and also at a greater frequency than that observed among placebo recipients are shown in Table 6. -0-

                               Table 6

   Vaccine-related Injection-site and Systemic Adverse Experiences*

----------------------------------------------------------------------

                                                    Aluminum-  Saline

                                          GARDASIL  Containing Placebo

                                           (N =      Placebo    (N =

Adverse Experience                          5088)  (N = 3470)    320)

(1 to 5 Days Postvaccination)                %          %         %

----------------------------------------------------------------------

Injection Site

    Pain                                    83.9      75.4      48.6

    Swelling                                25.4      15.8       7.3

    Erythema                                24.6      18.4      12.1

    Pruritus                                3.1        2.8       0.6

----------------------------------------------------------------------

                                          GARDASIL

                                           (N =          Placebo

Adverse Experience                          5088)      (N = 3790)

(1 to 15 Days Postvaccination)               %              %

----------------------------------------------------------------------

Systemic

    Fever                                   10.3           8.6

    Nausea                                  4.2            4.1

    Dizziness                               2.8            2.6

----------------------------------------------------------------------

* The vaccine-related adverse experiences that were observed among

 recipients of GARDASIL were at a frequency of at least 1.0% and also

 at a greater frequency than that observed among placebo recipients.

All-cause Common Systemic Adverse Experiences

All-cause systemic adverse experiences for female subjects that were observed at a frequency of greater than or equal to 1% where the incidence in the vaccine group was greater than or equal to the incidence in the placebo group are shown in Table 7. -0-

                               Table 7

            All-cause Common Systemic Adverse Experiences

----------------------------------------------------------------------

Adverse Experience                                    GARDASIL Placebo

(1 to 15 Days Postvaccination)                         (N =     (N =

                                                        5088)   3790)

                                                         %        %

----------------------------------------------------------------------

  Pyrexia                                               13.0    11.2

Nausea                                                  6.7      6.6

Nasopharyngitis                                         6.4      6.4

Dizziness                                               4.0      3.7

Diarrhea                                                3.6      3.5

Vomiting                                                2.4      1.9

Myalgia                                                 2.0      2.0

Cough                                                   2.0      1.5

Toothache                                               1.5      1.4

Upper respiratory tract infection                       1.5      1.5

Malaise                                                 1.4      1.2

Arthralgia                                              1.2      0.9

Insomnia                                                1.2      0.9

Nasal congestion                                        1.1      0.9

----------------------------------------------------------------------

Evaluation of Injection-site Adverse Experiences by Dose

An analysis of injection-site adverse experiences in female subjects by dose is shown in Table 8. Overall, 94.3% of subjects who received GARDASIL judged their injection-site adverse experience to be mild or moderate in intensity. -0-

                               Table 8

      Postdose Evaluation of Injection-site Adverse Experiences

----------------------------------------------------------------------


                                                Aluminum-Containing

                               Vaccine                 Placebo

                            (% occurrence)         (% occurrence)

======================================================================

                        Post- Post- Post- Post Post- Post- Post- Post

        Adverse         dose  dose  dose  Any  dose  dose  dose  Any

      Experience          1     2     3   Dose   1     2     3   Dose

----------------------------------------------------------------------

Pain                     63.4  60.7  62.7 83.9  57.0  47.8  49.5 75.4

   Mild/Moderate         62.5  59.7  61.2 81.1  56.6  47.3  48.9 74.1

   Severe                 0.9   1.0   1.5  2.8   0.4   0.5   0.6  1.3

----------------------------------------------------------------------

Swelling*                10.2  12.8  15.1 25.4   8.2   7.5   7.6 15.8

   Mild/Moderate          9.6  11.9  14.3 23.3   8.0   7.2   7.3 15.2

   Severe                 0.6   0.8   0.8  2.0   0.2   0.3   0.2  0.6

----------------------------------------------------------------------

Erythema*                 9.2  12.1  14.7 24.7   9.8   8.4   8.9 18.4

   Mild/Moderate          9.0  11.7  14.3 23.7   9.5   8.3   8.8 18.0

   Severe                 0.2   0.3   0.4  0.9   0.3   0.1   0.1  0.4

----------------------------------------------------------------------


                                                    Saline Placebo

                                                    (% occurrence)

======================================================================

                                                Post- Post- Post- Post

                    Adverse                     dose  dose  dose  Any

                   Experience                     1     2     3   Dose

----------------------------------------------------------------------

Pain                               

Posted: November 2007

View comments

Hide
(web5)